Treatment May 27, 2026 · 5:01 PM 7/10 positive

China Accepts New Lung Cancer Drug for Priority Review in First-Line Treatment

Dr. Rachel Mendez MD, Medical Science Writer

✨ Why this is good news

This article is about a new oral drug for a hard-to-treat form of lung cancer caused by specific genetic mutations.

Priority review speeds access.Chinese regulators granted the drug sunvozertinib priority review, which can cut months off the approval timeline. Before this, patients with EGFR exon 20 insertion mutations had limited first-line options and often faced long waits for experimental treatments.
Targets a hard-to-treat mutation.Sunvozertinib is designed specifically for EGFR exon 20 insertion mutations, which are genetically diverse and resist many standard lung cancer drugs. This news means patients with this challenging mutation now have a tailored therapy moving toward approval, instead of relying on less effective chemotherapy.
First-line oral therapy option.The drug is being pursued as an initial or first-line treatment, meaning newly diagnosed patients could take it as their first therapy. Previously, these patients often had to try multiple treatments before finding one that worked, but sunvozertinib could offer a simpler, earlier solution taken by mouth.
Addresses an unmet need in NSCLC.Non-small cell lung cancer with EGFR exon 20 insertions has had few approved targeted treatments, leaving many patients with poor outcomes. This priority review brings a new option closer to clinical use, potentially improving survival and quality of life for thousands of people in China with this specific lung cancer subtype.

Chinese regulators have accepted a new drug application for the oral targeted therapy sunvozertinib and granted it priority review, moving the treatment one step closer to becoming a first-line option for patients with a difficult to treat form of lung cancer.

The application, submitted by the biopharmaceutical company Dizal, seeks approval for sunvozertinib as an initial treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that carries EGFR exon 20 insertion mutations. These mutations are particularly challenging because of their high genetic diversity, and current first-line care relies heavily on chemotherapy. The company announced that the Center for Drug Evaluation of China’s National Medical Products Administration accepted the filing and designated it for priority review, which can shorten the standard review timeline.

The submission is backed by results from the WU-KONG28 study, a multinational Phase 3 trial conducted across 16 countries. In the trial, sunvozertinib was compared directly against platinum based chemotherapy doublets. The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression free survival. Full data is scheduled to be presented as a late breaking abstract at the upcoming 2026 American Society of Clinical Oncology annual meeting.

Globally, no oral targeted therapy has yet been approved for first line treatment of EGFR exon20ins NSCLC. Sunvozertinib has already received breakthrough therapy designations from both the U.S. Food and Drug Administration and China’s drug regulator for this specific patient population. It is currently approved in both the United States and China for patients whose disease has progressed after platinum based chemotherapy, making this expansion a significant step forward.

“The NDA acceptance and priority review designation for sunvozertinib in first line EGFR exon20ins NSCLC is an important step forward for us to make the drug available to our patients globally,” said Dr. Xiaolin Zhang, CEO of Dizal, in a statement. “Supported by positive results from WU-KONG28, we believe sunvozertinib has the potential to be a practice changing drug for this underserved patient population.” The company is also working to submit applications to other regulatory agencies worldwide.

If approved, the oral therapy could offer newly diagnosed patients a chemotherapy free, targeted treatment option. The company is moving quickly to bring the drug to more patients, with additional regulatory submissions expected in the near future.

Lung Cancer Oncology Priority Review Targeted Therapy

This article is for informational purposes only and does not constitute medical advice. The information presented is based on published research and official announcements. Always consult a qualified healthcare professional before making any medical decisions.

← Back to all stories